April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Tear Matrix Metalloproteinases and Myeloperoxidase Levels Following Boston Keratoprosthesis Type I surgery.
Author Affiliations & Notes
  • Marie-Claude Robert
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA
    Schepens Eye Research Institute, Boston, MA
  • Samer N Arafat
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA
    Schepens Eye Research Institute, Boston, MA
  • Sandra Spurr-Michaud
    Schepens Eye Research Institute, Boston, MA
  • James Chodosh
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA
  • Claes H Dohlman
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA
  • Ilene K Gipson
    Schepens Eye Research Institute, Boston, MA
  • Footnotes
    Commercial Relationships Marie-Claude Robert, None; Samer Arafat, None; Sandra Spurr-Michaud, None; James Chodosh, None; Claes Dohlman, None; Ilene Gipson, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4685. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marie-Claude Robert, Samer N Arafat, Sandra Spurr-Michaud, James Chodosh, Claes H Dohlman, Ilene K Gipson; Tear Matrix Metalloproteinases and Myeloperoxidase Levels Following Boston Keratoprosthesis Type I surgery.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4685. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the levels and activity of matrix metalloproteinases (MMPs), myeloperoxidase (MPO) and tissue inhibitor of metalloproteinase-a (TIMP-1) in tears of eyes with Boston Keratoprosthesis type I (KPro) and to correlate these markers with the well-established prognostic hierarchy for KPro surgery. Indeed, eyes with non-cicatricial disease, chemical burns and autoimmune disease have, in this order, an increasing risk of failure following KPro implantation.

Methods: In this prospective, non-interventional cohort study, bilateral tear washes were collected from patients with KPro. Tear fluid analysis for levels of MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MPO, and TIMP-1 was performed using a multianalyte bead-based enzyme-linked immunosorbent assay. Total MMP activity was determined using a fluorometric assay. Correlation studies were performed between the various analytes and the underlying diagnoses leading to KPro. In eyes with unilateral KPro, MMP and MPO levels were compared between the operated and non-operated eye.

Results: Of the fourteen patients participating in this study, two had an underlying diagnosis of autoimmune disease, two had chemical burn and ten had non-cicatricial diagnoses. Tear collection was performed an average of 8 years (range 1 month to 17 years) after initial KPro surgery. MMP-9 and MPO levels were elevated in all KPro tears. When compared to eyes with non-cicatricial diseases, eyes with autoimmune disease had higher tear levels MMP-8, MMP-9 and MPO while eyes with chemical burn had higher tear levels of MMP-9 and MPO only. The MMP-8 to TIMP-1 and MMP-9 to TIMP-1 ratios were 2.4 and 1.3 times higher in eyes with KPro when compared to the contralateral eyes without KPro.

Conclusions: Our study shows that the tears of eyes with KPro have constitutively high levels of MMPs even years after the initial insult and KPro surgery. This is particularly true for those eyes with autoimmune disease or chemical burn. In the presence of bilateral pathology, eyes with KPro seem to have higher MMP and MPO levels when compared to that of the contralateral non-KPro eye. The introduction of MMP inhibitors and/or additional anti-inflammatory prophylaxis may be warranted to suppress MMP activity and therefore, protect high-risk KPro eyes from corneal tissue melt.

Keywords: 575 keratoprostheses • 432 autoimmune disease • 557 inflammation  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×